From the Journals

Antiretroviral choice for pregnant women with HIV does not appear to impact birth outcomes


 

FROM NEW ENGLAND JOURNAL OF MEDICINE


One author reported stock from Abbott, AbbVie, Novartis, and Roche outside the submitted work; one author reported personal fees from Boehringer-Ingelheim; and five authors reported grants from pharmaceutical companies and Google outside the submitted work.

SOURCE: Rough K et al. N Engl J Med 2018;378:1593-603.

Pages

Recommended Reading

FDA approves new treatment for multidrug-resistant HIV
MDedge Family Medicine
Looking to increase PrEP uptake
MDedge Family Medicine
Efavirenz-based ART may hamper vaginal ring contraception
MDedge Family Medicine
High adverse events with TB prevention in HIV-infected pregnant women
MDedge Family Medicine
MicroRNAs flag liver damage in HIV-, HCV-infected persons
MDedge Family Medicine
VIDEO: Women living with HIV have more myocardial steatosis, reduced diastolic function
MDedge Family Medicine
Time to HIV rebound in infants off ART linked to birth health
MDedge Family Medicine
MDedge Daily News: Can androgen therapy improve male frailty?
MDedge Family Medicine
Medical marijuana’s ‘Catch-22’: Federal limits on research hinder patients’ relief
MDedge Family Medicine
Comorbidity occurs earlier and more commonly with HIV infection
MDedge Family Medicine